The Cross-Border Biotech Blog

CSRFeatImg

Welcome to your Canada in Science Review for August 28th, 2015! PLoS Med. 2015 Aug 25;12(8):e1001866. Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study.   J Cell Biol. 2015 Aug 24. pii: jcb.201501076. Polarized E-cadherin endocytosis directs actomyosin remodeling during embryonic wound repair.   Proc Natl Acad Sci U S A. 2015 Aug 17. pii: […]

read more


BBB_Part15_Logo

Market Exclusivity – Product Life-Cycle Management Market exclusivity is a critical component of valuation. When patent and regulatory exclusivity expire, generic versions of small molecule drugs will decimate the sales of the brand products. For the top-selling brand drugs, there may be 10 or more generic equivalents and the generic price may drop to 5% […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for August 24th, 2015!   We apologize for the delay, below is your Monday Deal Review for August 24th, 2015** In M&A news, Endo international completed a previously announced sale of the men’s and prostate health division of its American Medical Systems business to Boston Scientific for USD$1.65-billion. Meanwhile […]

read more


CSRFeatImg

Welcome to your Canada in Science Review for August 14th, 2015! Proc Natl Acad Sci U S A. 2015 Aug 10. pii: 201508826. Unbiased phosphoproteomic method identifies the initial effects of a methacrylic acid copolymer on macrophages.   EMBO J. 2015 Aug 7. pii: e201592237. A Ubl/ubiquitin switch in the activation of Parkin.   PLoS Genet. 2015 Aug 6;11(8):e1005429. […]

read more


BBB_Part14_Logo

Market Exclusivity – Regulatory Data Market exclusivity is a critical component of valuation. When patent exclusivity falls short of the expected 10 plus years, regulatory data exclusivity may provide some extra time before generics, biosimilars or other competitors can be approved.  NDAs or New Drug Applications are filed for new prescription drug products and must […]

read more


CSRFeatImg

Welcome to your Canada in Science Review for July 31st, 2015! N Engl J Med. 2015 Jul 30;373(5):438-447. Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.   Mol Ther. 2015 Jul 23. doi: 10.1038/mt.2015.129. miR-221/222 are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma.   N Engl J Med. 2015 Jul 23;373(4):307-16. Regional Nodal Irradiation in […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for July 27th, 2015! We apologize for the delay, below is your Monday Deal Review for July 13th, 20th and 27th, 2015** In M&A news, Valeant Pharmaceuticals International, Inc. announced the US$800 million acquisition of Mercury (Cayman) Holdings – the holding company of Amoun Pharmaceuticals. Meanwhile, ProNAi generated […]

read more


CSRFeatImg

Welcome to your Canada in Science Review for July 17th, 2015! Nat Biotechnol. 2015 Jul 13. doi: 10.1038/nbt.3294. Directed differentiation of cholangiocytes from human pluripotent stem cells.   Proc Natl Acad Sci U S A. 2015 Jul 13. pii: 201502966. A multidrug resistance plasmid contains the molecular switch for type VI secretion in Acinetobacter baumannii.   J Allergy […]

read more


BBB_Part13_Logo

Market Exclusivity – Patents Market exclusivity is a critical component of valuation. Patenting strategies, regulatory data exclusivity and product life-cycle management will give about 10 to 15 years of market exclusivity to most novel drugs. The patent system originated during the industrial revolution – the first U.S. patent law was enacted in 1790. The concept […]

read more


Q2_2015_Part2(v2)_Feat_Img

Sideways with moderate volatility for Tier 2 companies   In this blog, I am going to comment on the Q2 and H1 performance of the Tier 2 group of 52 companies with share prices of between $0.10 and $0.99 to start 2015. Q2 2015 Tier 2 Performance  Decliners outnumbered advancers by 29 to 23  Average […]

read more